The Major Advances of the Year in Breast Cancer: A Point of View After the ASCO 2025 Annual Meeting

At ASCO 2025, several practice-changing studies in breast cancer were presented. In HR+ early BC, the SOFT/TEXT 15-year update confirmed the benefit of ovarian suppression plus endocrine therapy, while OASIS-4 showed elinzanetant reduced endocrine-related vasomotor symptoms. In early TNBC, NRG-BR003 found no survival benefit from adding carboplatin. In HER2+ early breast cancer, omitting carboplatin preserved efficacy with better tolerability. In advanced disease, DESTINY-Breast09 established trastuzumab deruxtecan plus pertuzumab as superior first-line therapy. SERENA-6 and VERITAC-2 highlighted ESR1-targeted strategies, while ASCENT-04/KEYNOTE-D19 demonstrated sacituzumab govitecan plus pembrolizumab improved outcomes in PD-L1-positive advanced TNBC.